These results provide further evidence that FZD-targeting small molecules indeed provide a therapeutic opportunity in cancer types stratified for WNT dependence that is caused for example, by RNF43 mutations but potentially also by overexpression of WNTs or FZDs. This evidence concerns the gene RNF43 and cancer.